Literature DB >> 17147239

The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma.

Mary Lee H Villanueva1, Julie M Vose.   

Abstract

Hematopoietic stem cell transplantation has become an increasingly important treatment modality for hematologic malignancies. Autologous stem cell transplantation has become the standard of care in relapsed high-risk diffuse large B-cell lymphoma (DLBCL) patients who respond to reinduction therapy. The exact role of allogeneic transplantation in DLBCL is still unknown and it appears to be useful in only a select group of patients. The exact role of hematopoietic stem cell transplant in follicular lymphoma is evolving. The treatment of mantle cell lymphoma is challenging and stem cell transplantation may play an important role, as our understanding of the biology and natural history of this disease improves. This review focuses on studies evaluating the role of stem cell transplantation in non-Hodgkin lymphoma.

Entities:  

Mesh:

Year:  2006        PMID: 17147239

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  6 in total

1.  Standard chemotherapy is superior to high-dose chemotherapy with autologous stem cell transplantation on overall survival as the first-line therapy for patients with aggressive non-Hodgkin lymphoma: a meta-analysis.

Authors:  Jing Wang; Ping Zhan; Jian Ouyang; Bing Chen; Rongfu Zhou; Yonggong Yang
Journal:  Med Oncol       Date:  2010-04-06       Impact factor: 3.064

2.  Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products.

Authors:  Rakesh K Singh; Michelle L Varney; Cheryl Leutzinger; Julie M Vose; Philip J Bierman; Suleyman Buyukberber; Kazuhiko Ino; Kevin Loh; Craig Nichols; David Inwards; Robert Rifkin; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2007-04-20       Impact factor: 4.932

3.  Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.

Authors:  I Sánchez-Ortega; S Querol; M Encuentra; S Ortega; A Serra; J M Sanchez-Villegas; J R Grifols; M M Pujol-Balaguer; M Pujol-Bosch; J M Martí; T Garcia-Cerecedo; P Barba; J M Sancho; A Esquirol; J Sierra; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-09-15       Impact factor: 5.483

4.  Economic evaluation of plerixafor for stem cell mobilization.

Authors:  Steven M Kymes; Iskra Pusic; Dennis L Lambert; Martin Gregory; Kenneth R Carson; John F DiPersio
Journal:  Am J Manag Care       Date:  2012-01       Impact factor: 2.229

5.  The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.

Authors:  So Yeon Jeon; Ho-Young Yhim; Hee Sun Kim; Jeong-A Kim; Deok-Hwan Yang; Jae-Yong Kwak
Journal:  Korean J Intern Med       Date:  2018-01-08       Impact factor: 2.884

6.  Autologous Peripheral Blood Stem Cell Transplantation Among Lymphoproliferative Disease Patients: Factors Influencing Engraftment.

Authors:  Mohd Nazri Hassan; Hafizuddin Mohamed Fauzi; Azlan Husin; Rapiaah Mustaffa; Rosline Hassan; Mohd Ismail Ibrahim; Noor Haslina Mohd Noor
Journal:  Oman Med J       Date:  2019-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.